XML 51 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
ACQUISITIONS AND DIVESTITURES (Tables)
 12 Months Ended
Dec. 28, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Purchase Price Allocation
The purchase price allocation for acquisitions during fiscal years 2024, 2023, and 2022 was as follows:
Noveprim GroupSAMDI Tech, Inc.Explora BioLabs
November 30, 2023January 27, 2023April 5, 2022
(in thousands)
Trade receivables$1,308 $513 $7,679 
Inventories66,500 — — 
Other current assets (excluding cash)3,261 75 1,067 
Property, plant and equipment36,154 593 37,369 
Operating lease right-of-use asset, net104 — 48,613 
Goodwill (1)
190,024 37,129 215,752 
Definite-lived intangible assets9,500 33,070 70,100 
Other long-term assets (2)
167,907 6 556 
Deferred revenue— (43)(3,507)
Other current liabilities (16,268)(351)(15,507)
Operating lease right-of-use liabilities (Long-term)(97)— (57,193)
Deferred tax liabilities(12,984)(8,191)(18,601)
Other long-term liabilities(7,579)— (1,807)
Redeemable noncontrolling interest (3)
(45,426)— — 
Total purchase price allocation$392,404 $62,801 $284,521 
(1) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. Explora BioLabs had $5.0 million of goodwill due to prior asset acquisition that is deductible for tax purposes.
(2) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight-year useful life.
(3) Refer to Note 12 – Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.
Schedule of Finite-Lived Intangible Assets Acquired
The definite-lived intangible assets acquired during fiscal years 2024, 2023, and 2022 were as follows:
Noveprim GroupSAMDI Tech, Inc.Explora Biolabs
Definite-Lived Intangible Assets(in thousands)
Client relationships$— $23,400 $64,000 
Other intangible assets9,500 9,670 6,100 
Total definite-lived intangible assets$9,500 $33,070 $70,100 
Weighted Average Amortization Life(in years)
Client relationships— 1513
Other intangible assets774
Total definite-lived intangible assets71212
Schedule of Major Classes of Assets and Liabilities Associated with Divestitures
The carrying amounts of the major classes of assets and liabilities associated with this divestiture were as follows:
December 19, 2022
Avian
(in thousands)
Assets
Current assets$30,545 
Property, plant, and equipment, net24,602 
Operating lease right-of-use assets, net611 
Goodwill3,168 
Client relationships, net1,629 
Other assets10 
Total assets$60,565 
Liabilities
Current liabilities$8,139 
Operating lease right-of-use liabilities331 
Long-term liabilities— 
Total liabilities$8,470